A Phase I Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 against Crimean Congo Hemorrhagic Fever (CCHF-NP-1)

2023-508556-18-00 Protocol CCHF-NP-1 Human pharmacology (Phase I) - First administration to humans Ended

Start 25 Sep 2024 · End 17 Mar 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol CCHF-NP-1

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 15
Countries 1
Sites 1

Crimean Congo Hemorrhagic Fever

Key facts

Sponsor
Karolinska Institutet
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Virus Diseases [C02]
Trial duration
25 Sep 2024 → 17 Mar 2026
Decision date (initial)
2024-05-03
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Crimean Congo Hemorrhagic Fever

VersionLevelCodeTermSystem organ class
20.1 PT 10010685 Congo-Crimean haemorrhagic fever 100000004862

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Karolinska Institutet

Sponsor organisation
Karolinska Institutet
Address
Alfred Nobels Alle 8, Flemingsberg Flemingsberg
City
Huddinge
Postcode
141 52
Country
Sweden

Scientific contact point

Organisation
Karolinska Institutet
Contact name
Matti Sällberg

Public contact point

Organisation
Karolinska Institutet
Contact name
Matti Sällberg

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Sweden Ended 15 1
Rest of world 0

Investigational sites

Sweden

1 site · Ended
Karolinska University Hospital
Dept. of Infectious Diseases, Halsovagen, Flemingsberg, Huddinge

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Sweden 2024-09-25 2026-03-17 2024-11-12

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-07 Sweden Acceptable with conditions
2024-05-02
2024-05-03
2 SUBSTANTIAL MODIFICATION SM-1 2024-06-07 Sweden Acceptable
2024-08-05
2024-08-06